The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ICLE 2022 | Focusing on allogeneic CAR T-cell therapies for myeloma
Tuna Mutis, MD, PhD, Amsterdam University Medical Center, Amsterdam, The Netherlands, discusses the advantages of using allogeneic sources for chimeric antigen receptor (CAR) T-cell therapy, especially for the treatment of multiple myeloma. Patients with myeloma tend to be older and as result of their age and disease status, the T-cells will be dysfunctional and unsuitable for the production of CAR T-cell therapies. Allogeneic T-cells will enhance the efficacy of cell therapies and additionally reduce production costs. This interview took place at the International Conference on Lymphocyte Engineering (ICLE) 2022.
